Sign In
Buy APRE
$0.762
-0.0022 (-0.288%)
At Close: Jun 03, 2026
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan h
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:25am, Thursday, 29'th Jan 2026
DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatme
New Strong Sell Stocks for January 19th
06:15am, Monday, 19'th Jan 2026
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
New Strong Sell Stocks for Jan. 14
05:25am, Wednesday, 14'th Jan 2026
APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December
05:22am, Monday, 29'th Dec 2025
Aprea Therapeutics, Inc. (NASDAQ: APRE - Get Free Report) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 34,578 shares, a decline of 41
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
08:30am, Thursday, 18'th Dec 2025
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatme
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:30am, Tuesday, 09'th Dec 2025
Financing from new and existing healthcare focused investors The proceeds are expected to extend the Company's cash runway into Q1 2027, with potential inflection points anticipated in its clinical pr
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
08:30am, Wednesday, 12'th Nov 2025
APR-1051 (WEE1 kinase inhibitor): In ongoing Phase 1 ACESOT-1051dose-escalation trial, 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pret
DOYLESTOWN, Pa., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatme
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
08:00am, Wednesday, 15'th Oct 2025
ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation study Further ATRN-119 monotherapy enrollment paused with strategic focus on high-value combinatio
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
08:00am, Tuesday, 14'th Oct 2025
DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatme
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
08:30am, Thursday, 28'th Aug 2025
DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatm
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
08:00am, Tuesday, 12'th Aug 2025
Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor,
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
08:00am, Wednesday, 14'th May 2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial
